


**FIGURE 1**






**FIGURE 2A**

FIGURE 2B



**FIGURE 3A**

**FIGURE 3B**

**FIGURE 4A**



**FIGURE 4B**

FIGURE 5A







**FIGURE 5B**

FIGURE 6A



**FIGURE 6B**

**FIGURE 7A**




**FIGURE 7B**

FIGURE 8A



**FIGURE 8B**

**FIGURE 9**

**Weight of Human Colon Adenocarcinoma (HT-29) in CD-1  
Nude Mice Treated with Combination Therapy**





FIGURE 10



## FIGURE 11

### Growth of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice







FIGURE 12




**FIGURE 13**

**FIGURE 14****Weight of Human Prostate Carcinoma (PC-3)  
in SCID Mice**


## FIGURE 15

Weight of Human Prostate Carcinoma(DU145)  
in SCID Mice


A



B




## FIGURE 16




## FIGURE 17

### Weight of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice

A



B



### Growth of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice

C





FIGURE 18


Growth of Human Ovary Adenocarcinoma (SK-OV-3)  
In CD-1 Nude Mice




## FIGURE 19

**A**

## Growth of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice

**B**


## Weight of Human Pancreatic Carcinoma (BxPC-3) In CD-1 Nude Mice



## FIGURE 20


### Growth of Human Cervix Epitheloid Carcinoma (HeLa S3-HU-Resistance) in SCID Mice

A




### Weight of Human Cervix Epitheloid Carcinoma (HeLa S3-HU-Resistance) in SCID Mice

B



## FIGURE 21

**Weight of Human Cisplatin-Resistant Breast Adenocarcinoma  
Implanted at the Fat Pad of SCID Mice**




Statistical Analysis:	P value
Saline : Cisplatin	0.0834
Saline : Taxol	<0.0001
Saline : SEQ ID NO:1	<0.0001
SEQ ID NO:1 : Cisplatin	0.0007
SEQ ID NO:1 : Taxol	0.9547


## FIGURE 22

**Growth Of Human Breast Cancer (MDA-CDDP-S4) In CB-17  
SCID Mice Treated With Taxol, SEQ ID NO:1, and Taxol+SEQ ID NO:1  
(Orthotopical transplant)**


A



B



C




SEQ ID NO:1: Taxol P=0.0133  
SEQ ID NO:1: SEQ ID NO:1+Taxol P=0.0009  
Taxol : SEQ ID NO:1+Taxol P<0.0001


## FIGURE 23



Weight of Human Taxol-Resistant Breast Adenocarcinoma (MDA-MB435-To.1) Implanted at the Fat Pad of SCID Mice

A



B




**FIGURE 24****Growth of Human Breast Adenocarcinoma (MDA-MB435-To. 1)  
in SCID Mice****A****Weight of Human Breast Adenocarcinoma (MDA-MB-435-To. 1)  
in SCID Mice****B**

## FIGURE 25


### Growth of Promyelocytic Leukemia HL-60 (Taxol-Resistant) in SCID Mice




A



### Weight of Human Promyelocytic Leukemia HL-60 (Taxol-Resistant) in SCID Mice

B



**FIGURE 26****Growth of Human Multi-Drug Resistance Colon Adenocarcinoma (LS513) In SCID Mice****A****B****Weight of Human Colon Multi-Drug Resistance Carcinoma (LS513) In SCID Mice****C**

## FIGURE 27

>gi|4557844|ref|NM\_001034.1| Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA

```

CCCAGGGCAGCCAATGGGAAGGGTCGGAGGCATGGCACAGCCAATGGGAAGGGCCGGGGCACCAAAGCC
AATGGGAAGGGCCGGAGCGCGCCGGCGGGAGATTAAAGGCTGCTGGAGTGAGGGGTGCCCCGTGCAC
CTGTCCACGGCGTCCCTGCTCGCTCGCTCGCTCGCCCTCCACTATGCTCTCCCTCCGTG
TCCCGCTCGCGCCCATCACGGACCGCAGCAGCTGAGCTCTGAGCAAGGGGCTCAGCTTGGCTGA
CAAGGAGAACACGCCCGGGGGCGTGGAGGGACCCGCGTGGCCAGCAAGACCCCGAGGAGGATCTC
CAGGAGCCACGGAGCGAAAATCAAAGCAGCTGCCCCCGCTGGAGGATGAGCCGCTGCTGAGAGAAA
ACCCCCCGCGCTTGTCACTCTCCCCATCGAGTACCATGATATCTGAGAGATGATAAGAAGGGCAGAGG
TTCCCTTGGACCGCCGAGGGTTGACCTCTCCAAGGACATTAGCAGCAGTGGAAATCCCTGAAACCCGAG
GAGGATATTTATATCCCATGTCAGGCTTCTTGTGAGCAAGCAGTGGAGGATATGGAAACCTTGG
TGGAGGCTTTAGCCAGAAGCTGAGATTACAGAAGCCCGCTGTTCTATGGCTTCCAAATTGCCATGG
AAACATACATTCTGAAATGTTAGTCCTTATTGACACTTACATAAAAGATCCAAAGAAAGGGAAATTT
CTCTTCATGCCATTGAAACGATGCCCTGTGTCAGAAGAAGGAGACTGGGCTTGGCTGGATTGGGG
ACAAAGAGGCTACCTATGGTGAACGCTGTTGAGCCTTGTGAGTGGAGGATTTTCTTCCGGTTC
TTTGCGTCGATATTCTGGCTCAAGAAACGAGGACTGATGCCCTCACATTCTGAACTTATT
AGCAGAGATGAGGGTTTACACTGTGATTGGCTGGCTGAGTTGACAAACCTGGTACACAAACATCGG
AGGAGAGACTAACAGAGAAAATATTATCAATGCTGTTGCGATAGAACAGGAGCTCTCACTGAGGCCTTGG
TGTGAAGGCTATTGGGATGAAATTGCACTCTAATGAAGAACATTGAGTTTGTGCGAGACAGACATTG
CTGGAACTGGGTTTGTAGCAAGGTTTCAGAGTAGAGAACCCATTGACTTTATGGAGAATATTTCAGTGG
AAGGAAAGACTAACTCTTGAGAAGAGAGTAGGGCAGTATCAGAGGATGGGAGTGATGTCAGTCCAAAC
AGAGAAATTCTTTACCTTGGATGCTGACTTCTAAATGAACTGAGAGATGTCGGCTTACTTGGCTGAAATT
TTTTTCCATCTCATAGAAAATCAGCTGAAGTGTACCAACTAGCCACACCATGAAATTGTCGGTAATGTT
TCATTAACAGCATTTAAACTGCTGCTGACTCACCTGACAGTGGCTTGTGACTTACCTGAGTGGCTTGTAGT
ATCACCTTTGCCAGAGGGCTGGCTGTGACTTACCATGAGTGGCTTGTGACTTACCTGAGTGGCTTGTAGT
AAGTGAGGGTGCACCTTTAGTGAGCTTAGCACAGCGGGATTAAACAGCTCCTTAAACCAGCACAGCCAGT
TAAAAGATGCAAGCCTCACTGCTTCAACGAGATTAAATGTTACTTAAATATAAAACCTGGCACTTTACA
AAACAATAAACATTGTTTGACTCACGGCGGCGATAATAGCTTGTGAAATTGTTGCTACACCAAATA
CATTCCTCTGACCAACTAATGGGAGCCAATTACAACATTCAACTGAGCTAAAGTAAGTTAAACTTGTGTA
GACTAAGGAGATGAAATTTTAAAGTTTAAATTAAATGAAATTAAACCTTAAAGTCAGTGGCTTGTAGT
CCTGTGTAACCTAGATTAGTCAGTTGGTGCAGATAGGAGACAGGTTGTTTATCTGCTGGCTT
GTGAGTGCTCTGGGATTCTCTGCCCTCTGAGTAGAGTGGCTGGGATAAAGGAATCTCTGAGGGCAA
GGAGCTTCTTAAGTTAAATCACTAGAAAATTAGGGGCTGATCTGGGCTTCAATATGTTGAGAAGCCGTT
CATTTTATTCTCACTGTTTCTCAACGCTGTTGAGGAAATTCTGAGAGAGTTTCTCATAT
GTGGGAGGTAAGGTAGTATTGAAAATTCAAGTCATCTTAAACAAATGATCCACCTAAGATCTTGCC
CCTGTTAAGTGGTGAATCAACTAGAGGTGGCTTCAAGTTGTCATTCTAGTTGTTGCTGTAAG
TAGGTTGTTGAGTTAATTCAATTATATTACTATGTCGTTAAATCAGAAATTTTTATTATCTATGTT
CTCTAGATTACCTGAGTTCAAAAAAAAAAAAAAA

```